Alnylam Pharmaceuticals Inc (ALNY): Next-Year EPS Estimate 42.34%
As of 2026-06-04, Alnylam Pharmaceuticals Inc (ALNY) has a next-year EPS growth estimate of 42.34%.
On 2026-05-20, analyst consensus for ALNY's next-year EPS growth shifted from 44.02% to 42.34% — a negative change of 1.68 percentage points. The revised estimate has been sustained across 12 subsequent trading sessions. Current-year growth is projected at 221.64%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 42.34%
- EPS growth this year
- 221.64%
- EPS next quarter (est)
- $1.63
- Last price
- $303.64
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 42.34% | 221.64% | $1.63 | $303.64 |
| 2026-06-03 | 42.34% | 221.64% | $1.63 | $292.58 |
| 2026-06-02 | 42.34% | 221.64% | $1.63 | $286.12 |
| 2026-06-01 | 42.34% | 221.64% | $1.63 | $295.63 |
| 2026-05-31 | 42.34% | 221.64% | $1.63 | $301.98 |
| 2026-05-28 | 42.34% | 221.64% | $1.63 | $305.06 |
| 2026-05-27 | 42.34% | 221.64% | $1.63 | $295.63 |
| 2026-05-26 | 42.34% | 221.64% | $1.63 | $295.50 |
| 2026-05-25 | 42.34% | 221.64% | $1.63 | $297.45 |
| 2026-05-24 | 42.34% | 221.64% | $1.63 | $297.45 |
| 2026-05-21 | 42.34% | 221.64% | $1.63 | $300.51 |
| 2026-05-20 | 42.34% | 221.64% | $1.63 | $298.48 |
| 2026-05-19 | 44.02% | 217.25% | $1.61 | $294.30 |
| 2026-05-18 | 44.02% | 217.25% | $1.61 | $286.27 |
| 2026-05-17 | 44.02% | 217.25% | $1.61 | $286.98 |
| 2026-05-14 | 44.02% | 217.25% | $1.61 | $293.45 |
| 2026-05-13 | 44.02% | 217.25% | $1.61 | $292.11 |
| 2026-05-12 | 44.02% | 217.25% | $1.61 | $292.03 |
| 2026-05-11 | 44.02% | 217.25% | $1.61 | $284.84 |
| 2026-05-10 | 44.02% | 217.25% | $1.61 | $295.05 |
| 2026-05-07 | 44.02% | 217.25% | $1.61 | $295.91 |
| 2026-05-06 | 44.02% | 217.25% | $1.61 | $303.00 |
| 2026-05-05 | 44.02% | 217.25% | $1.61 | $301.11 |
| 2026-05-04 | 46.10% | 210.53% | $1.58 | $297.92 |
| 2026-05-03 | 46.10% | 210.53% | $1.58 | $296.11 |
| 2026-04-30 | 53.64% | 186.97% | $1.49 | $309.49 |
| 2026-04-29 | 55.29% | 187.46% | $0.90 | $301.19 |
| 2026-04-28 | 55.29% | 187.46% | $0.90 | $302.11 |
| 2026-04-27 | 55.29% | 187.46% | $0.90 | $308.51 |
| 2026-04-26 | 55.29% | 187.46% | $0.90 | $305.54 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Alnylam Pharmaceuticals Inc (ALNY) has a next-year EPS growth estimate of 42.34%, based on analyst consensus.
When was the latest EPS estimate revision for ALNY?▾
The most recent revision occurred on 2026-05-20, when analysts adjusted the next-year EPS growth estimate from 44.02% to 42.34%.
What sector and industry does Alnylam Pharmaceuticals Inc belong to?▾
Alnylam Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ALNY appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Alnylam Pharmaceuticals Inc (ALNY) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports